The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology and to Novel Treatment Approaches
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Six decades after the introduction of dopamine D2-receptor-based antipsychotics, schizophrenia remains one of the most severe and difficult-to-treat mental disorders. While a range of alternative therapeutic targets, such as the glutamatergic system, have attracted attention for negative symptoms and cognitive dysfunction, novel treatments for the core symptoms of schizophrenia remain unproven.
The endocannabinoid system (ECS) is a largely overlooked brain homeostatic system that is relevant to both the pathophysiology and treatment of schizophrenia.
Subscribe to read the entire article
Buy this Article as a PDF